Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    1172191 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia
Conditions: T-Cell Large Granular Lymphocytic Leukemia;   Leukemia, T-Cell Large Granular Lymphocytic
Intervention: Biological: Hu-MiK-Beta-1
2 Completed
Has Results
Anti-Tac for Treatment of Leukemia
Conditions: HTLV-I Infection;   T Cell Leukemia
Intervention: Biological: daclizumab

Indicates status has not been verified in more than two years